Confirming the Diagnosis: Labs and Genetics

The journey to a diagnosis of MCEE deficiency (Methylmalonyl-CoA Epimerase deficiency) often begins with a phone call about an “abnormal” newborn screen. Because this condition is so rare and its chemical “signature” overlaps with other metabolic disorders, the path to a final answer involves multiple layers of testing, ranging from simple blood draws to advanced genetic sequencing ^[1][2].

The First Signal: Newborn Screening

In most cases, MCEE deficiency is first flagged because of an elevated level of propionylcarnitine (C3) on a newborn screen ^[3]. This marker is a byproduct of the body’s attempt to process certain proteins and fats.

However, a high C3 level is not a diagnosis. It is merely a signal that the “relay race” of metabolism is blocked somewhere along the line. For children with MCEE deficiency, the initial screen can be tricky for two reasons:

• Normal MMA: In the first few days of life, methylmalonic acid (MMA) levels may actually be normal or only slightly elevated ^[1]. It often takes more time for this specific acid to build up to detectable levels.
• Normal Homocysteine: Unlike some other forms of MMA that involve Vitamin B12 processing, MCEE deficiency typically shows a normal level of homocysteine (an amino acid) ^[1][4].

The “Great Mimicker”

MCEE deficiency is famous in the medical world for mimicking other conditions. Because the metabolic block happens after the first step but before the last, the buildup of chemicals can look exactly like two other serious disorders ^[5][2]:

1. Propionic Acidemia (PA): Because C3 and methylcitrate are often elevated in both, MCEE deficiency is frequently suspected to be PA at first ^[2][6].
2. Classic MMA (MMUT): Because methylmalonic acid eventually rises, it can also look like the more common, often more severe, mutase-deficiency form of MMA ^[7].

Doctors look for “biochemical clues” to tell them apart. For example, if the body’s propionyl-CoA carboxylase enzyme is working normally but MMA is still rising, it is suggestive of MCEE rather than Propionic Acidemia ^[2]. However, this pattern is not purely diagnostic on its own, and further testing is always needed.

Essential Confirmatory Tests

When a newborn screen comes back abnormal, doctors order “second-tier” or confirmatory tests to look for a more specific pattern. These typically include:

• Plasma Acylcarnitine Profile: To confirm the high C3 level ^[3].
• Quantitative Plasma and Urine MMA: To measure exactly how much methylmalonic acid is building up ^[1][6].
• Urine Organic Acids: To look for methylcitrate and 3-hydroxypropionate, which are key markers of a backup in this pathway ^[8][5].
• Total Homocysteine: To help distinguish “isolated” MMA (like MCEE) from “combined” disorders that involve both MMA and homocystinuria ^[4].

Ruling Out Vitamin B12 Deficiency

Before finalizing a genetic diagnosis, your doctor must rule out acquired Vitamin B12 deficiency. If a mother is low in B12 (perhaps due to diet or an underlying health issue), her baby may have high MMA levels at birth ^[9]. This is not a genetic disorder, but rather a nutritional one that can be treated with supplements. Doctors evaluate serum B12, total homocysteine, complete blood counts (CBC), and the clinical context to rule this out ^[10][11].

Genetic Testing: The Final Step

While biochemical testing narrows down the diagnosis, molecular genetic testing is required to confirm MCEE deficiency ^[8]. By sequencing the MCEE gene, scientists look for “variants” (mutations) that prevent the epimerase enzyme from working ^[6].

MCEE deficiency follows an autosomal recessive inheritance pattern. Confirmation generally requires finding two pathogenic (disease-causing) or likely pathogenic variants in the gene. This means:

• The child must inherit two copies of the non-working gene—one from each parent ^[8].
• The parents are typically “carriers,” meaning they have one working copy and one non-working copy, and usually have no health issues themselves.

A negative test or finding a Variant of Uncertain Significance (VUS) does not completely establish or exclude the diagnosis by itself; interpretation depends on the accompanying biochemical findings. Genetic testing helps distinguish MCEE from other rare genetic types of MMA, such as cblA or cblB, ensuring the right management strategy is applied ^[4][12].